Navigation Links
Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma
Date:11/25/2008

200 Patients Enrolled in Clinical Trial to Assess Survival of Patients Receiving Litx versus Standard of Care Therapies for Unresectable Hepatocellular Carcinoma

BELLEVUE, Wash., Nov. 25 /PRNewswire/ -- Light Sciences Oncology, Inc. (LSO) today announced the completion of enrollment in a global Phase 3 clinical trial of Light Infusion Therapy(TM) (Litx(TM)) as a treatment for unresectable hepatocellular carcinoma (HCC), also known as hepatoma or primary liver cancer.

The two-armed, randomized clinical trial has enrolled 200 patients at sites in the Philippines, Korea, India, Malaysia, Thailand, Hong Kong, Singapore, Serbia, Poland, Croatia, and Italy. The primary endpoint of the clinical trial is to assess the survival of patients receiving Litx therapy versus those receiving standard-of-care therapies.

"We are pleased to have enrolled the final patient in this pivotal clinical trial of Litx in primary liver cancer," said Llew Keltner, M.D., Ph.D., president and CEO of Light Sciences Oncology. "We look forward to seeing a statistically significant survival benefit of Litx and proceeding with a New Drug Application to the U.S. FDA, EMEA, and other regulatory authorities in 2009."

HCC represents a great unmet medical need, with no effective treatments now available for the vast majority of patients. According to the 2005 edition of Cancer, Principles & Practice of Oncology, there are approximately one million new cases of HCC worldwide each year and, according to an article published in the Journal of Hepatology in 2004, HCC kills approximately one million people worldwide each year.

About Light-Infusion Therapy (Litx)

Litx is designed as an entirely new mode of therapy compared with the older, laser-based generation of light-activated drug therapies. The single-use, disposable Litx device uses light-emitting diodes (LEDs) to activate LS11(
'/>"/>

SOURCE Light Sciences Oncology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
2. Opportunities to Highlight Type 1 Diabetes in November
3. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
4. Battelle Scientists Named on Patent for Making Oxygen From Light and Water
5. New Studies Highlight Benefits of Coblation(R)-Assisted Procedures in Airway Fire Prevention and Endoscopic Sinus Surgery
6. Symposium Highlights Yale Study Indicating Role of AHCC(R) for Immune System Enhancement and as a Promising Cancer Preventative
7. Theranostics Health Receives Green Light to Perform Clinical Testing
8. September 2008 Mayo Clinic Health Letter Highlights Cataract Removal, Severe Headache and Dual Energy X-Ray Imaging
9. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
10. August 2008 Mayo Clinic Womens HealthSource Highlights Avoiding Blood Pressure Increase at Menopause, Healthful Benefits of Dark Chocolate and Scheduling a Colorectal Exam
11. New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Today the U.S. Food and Drug Administration ... prevention of serogroup B meningococcal disease in ... Trumenba®, which received FDA approval in October, represent a ... "I have heard over and over ...
(Date:1/23/2015)... , Jan. 23, 2015  The Partnership to Fight Chronic Disease ... health care leaders and a new study analyzing the impact ... PFCD is a nationwide coalition working to educate policy makers and ... at the Capitol was focused on how the Iowa ...
(Date:1/23/2015)... ATLANTA , Jan. 23, 2015 More than a ... a quarter of those with private insurance, filled a prescription ... to a report in this week,s Morbidity and Mortality Weekly ... health care providers to treat moderate to severe pain.  They ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3
... Ustekinumab ... in Nearly 2,000 Patients, HORSHAM, ... International NV announced today that regulatory,applications have been submitted requesting ... Europe for the treatment of adult,patients with chronic moderate to ...
... Phase III Open Label Trial Published in Online Edition ... ... Soliris(R),(eculizumab) therapy reduced hemolysis and improved fatigue, overall,quality of life and ... called paroxysmal nocturnal hemoglobinuria (PNH), according,to an analysis of the Phase ...
Cached Medicine Technology:Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis 2Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis 3Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients 2Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients 3Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients 4Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients 5Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients 6Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients 7
(Date:1/22/2015)... Deer Path of Huntley -- a BMA ... Hour from 3 p.m. to 4 p.m. on Feb. 13. , ... Illinois, serves adults with physical disabilities between the ages of 22 ... treats, games and sweetheart-themed karaoke. , For more information about the ...
(Date:1/22/2015)... Liberty University has received accreditation for its ... the Council for Accreditation of Counseling & Related Educational ... Center for Counseling & Family Studies , is under the ... new School of Behavioral Sciences. Prior to the formation of ...
(Date:1/22/2015)... The City of West Hollywood hosted a news conference ... 42nd anniversary of the Supreme Court decision Roe v. Wade, which ... since the Roe vs. Wade decision and the fight to protect ... said City of West Hollywood Councilmember Abbe Land. “We need to ...
(Date:1/22/2015)... January 22, 2015 Gabe’s Chemo Duck Program is ... the first app ever created for kids with cancer. The Chemo ... and devices, is filled with enjoyable games to help children of ... The free app helps to keep kids entertained, educated and at ...
(Date:1/22/2015)... a seasoned and trusted leader who consistently delivers trendy dresses ... it lead the wedding dress industry into the future. Today, ... the global market. , “The CEO of VogueQueen is uniquely ... continuing the goal of operational excellence and giving back to ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2
... body of the release., SAN DIEGO -- The ... chronic lymphocytic leukemia (CLL) has unearthed several new altered ... that could potentially help doctors predict whether an individual ... years, say scientists from Dana-Farber Cancer Institute and the ...
... Jersey has its share of underserved children, according to a ... state,s children between 3 and 18 received no dental care ... almost one-third of the state,s children received no care, the ... were still likely to forgo visits to the dentist. ...
... Scientists have discovered a new way to target cancer through ... The findings, published today [12 Dec] in the journal ... by producing their own blood vessels. Cancer cells ... blood vessels grow, helping deliver oxygen and sugars to the ...
... Dec. 12 (HealthDay News) -- Severe side effects may be ... taking drugs that can help prevent a tumor,s return, a ... gap between what these breast cancer patients tell their doctors ... to the study authors from Northwestern University in Chicago. ...
... , DETROIT Researchers at Henry Ford Hospital have found ... only patients consistently took their medication as prescribed. Moreover, ... at least 75 percent of their prescribed dose, according to ... on the onset and degree of symptoms. Henry Ford ...
... December 11, 2011) Lymphoma and myeloma are both ... blood cells, and commonly involve lymph nodes and the ... the treatment of these diseases, they remain a significant ... unique treatment approaches and targets for lymphoma and myeloma ...
Cached Medicine News:Health News:Massive DNA search uncovers new mutations driving blood cancer 2Health News:Massive DNA search uncovers new mutations driving blood cancer 3Health News:Rutgers Study: When it comes to use of dental services, not all NJ youngsters are equal 2Health News:Rutgers Study: When it comes to use of dental services, not all NJ youngsters are equal 3Health News:Scientists discover new way to target cancer 2Health News:Side Effects Cause Many Older Women to Drop Breast Cancer Drugs 2Health News:Improved medication use could reduce severe asthma attacks 2Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 2Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 3Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 4Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 5Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 6Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 7Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 8Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 9
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
... The 5mm AEM Laparoscopic Instruments incorporate ... AEM Instruments are shielded and monitored to ... of the instrument caused by insulation failure ... risk. The protective shield built into all ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...
Medicine Products: